Patient Results for Moderate to Severe Plaque PsO | TREMFYA® (guselkumab) HCP
  1. Efficacy in PsO
  2. Before-and-after

SEARCH THE TREMFYA® SITE

IN MODERATE TO SEVERE PLAQUE PsO

See clearer skin
with TREMFYA®*

left

right

Age:
36

BMI:
31.1 kg/m2

Baseline BSA
involvement:
54%

Psoriasis duration:
12 years

Previous therapies:
topicals, biologics

*Individual results may vary. Plaque psoriasis photos are of a real patient from VOYAGE 2 who received TREMFYA® 100 mg at Week 0 and 4, then q8w thereafter through Week 48. Other areas affected (not shown) yielded similar results to those depicted here. Clinical photos shown here are from Week 0, Week 16, and Week 48. Photos are for illustrative purposes only and are used with permission from Janssen Biotech, Inc.

BMI=body mass index; BSA=body surface area.

Reference: 1. Data on file. Janssen Biotech, Inc.

Patient photos represent results captured at baseline (Week 0), Week 4, and Week 16 outside of clinical trials.
*Individual results may vary.

Reference: 1. Data on file. Janssen Biotech, Inc.

Patient photos represent results captured at baseline (Week 0) and Week 16 outside of clinical trials.
*Individual results may vary.
Photos courtesy of Michael D. Overcash, MPAS, PA-C, DSDPA.

Reference: 1. Data on file. Janssen Biotech, Inc.

Patient photos represent results captured at baseline (Week 0) and Week 16 outside of clinical trials.
*Individual results may vary.
Photos courtesy of Dr. Nicole Seminara.

Reference: 1. Data on file. Janssen Biotech, Inc.

Patient photos represent results captured at baseline (Week 0) and Week 16 outside of clinical trials.
*Individual results may vary.

Reference: 1. Data on file. Janssen Biotech, Inc.

Back to Top